Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Aegon successfully sells 12.5 million shares in a.s.r.

(NYSE:AEG) NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION ...

How does this offering compare in size, pricing, and timing to recent equity raises by peer insurers in the sector? What are the intended uses of the proceeds from this equity offering and how might they affect Aegon's strategic initiatives? How will the sale of 12.5 million shares impact AEG's earnings per share and overall dilution?
Symbol: AEG
Equity offering
11 days ago
Read more globenewswire

Sampo plc’s share buybacks 2 September 2025

(SAMPO) Sampo plc, stock exchange release, 3 September 2025 at 8:30 am EEST

How does this buyback program compare with recent buyback activity of peer insurers in the Nordic market? What is the funding source for the buyback and does it impact Sampo's capital adequacy or dividend policy? How will the announced share buyback size and timing affect Sampo's earnings per share and valuation multiples?
Symbol: SAMPO
Buybacks
11 days ago
Read more globenewswire

Nova Announces Pricing of Upsized Private Offering of $650 Million of 0.00% Convertible Senior Notes due 2030

(NASDAQ:NVMI) REHOVOT, Israel, Sept. 3, 2025 /PRNewswire/ -- Nova (NASDAQ: NVMI), a leading innovator and a key provider of advanced metrology and process control solutions used in semiconductor ma...

What are the market’s expectations for the note’s pricing relative to peers in the semiconductor equipment sector? What is the conversion price and how does it compare to NVMI's current share price and implied dilution? How will the zero‑coupon convertible note issuance affect NVMI's cash flow and balance sheet metrics?
Symbol: NVMI
Debt
11 days ago
Read more prnewswire

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

(NASDAQ:VALN) Saint-Herblain (France), September 3rd, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme ...

How does VLA15’s efficacy, safety profile, and pricing potential compare to existing or pipeline Lyme disease vaccines from competitors? What is the expected timeline for regulatory approval and commercial launch of VLA15, and how does that align with market demand for a Lyme vaccine? How will the Phase 2 results affect Valneva’s short‑term stock momentum and volatility?
Symbol: VALN
Clinical trials
11 days ago
Read more globenewswire

Lyft Announces Pricing of Offering of $450 million of Convertible Senior Notes

(NASDAQ:LYFT) SAN FRANCISCO--(BUSINESS WIRE)--Lyft, Inc. (“Lyft”) (NASDAQ: LYFT) today announced the pricing of $450 million aggregate principal amount of Convertible Senior Notes due 2030 (the “no...

Will the proceeds from the notes support Lyft’s growth initiatives or liquidity needs, and how might this influence the stock’s price trajectory? What are the conversion terms and yield on the notes, and how do they compare to current market rates and competitor financing structures? How will the issuance of $450 million in convertible senior notes affect Lyft’s equity dilution and capital structure?
Symbol: LYFT
Financing
12 days ago
Read more businesswire